ESMO - Eur. Oncology· @myESMO · X·· 23 小时前评分45
正文 · 原文
#ESMO26: With long-awaited positive survival outcomes for a personalised #mRNA #NeoantigenVaccine, a key question discussed by John Haanen in his Editorial is how to make #CellularTherapies practical, scalable and sustainable
#InsightsbyESMO ➡️ https://ow.ly/8wqg5100Kzp
122 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com